Backgrounds The presence of C5 circulating tumor cells (CTCs) in 7.5 ml blood is a poor prognostic marker in metastatic breast cancer (MBC). However, the role of human epidermal growth factor receptor 2 (HER2) status in CTCs is not known.
Introduction
Despite the development of new agents, metastatic breast cancer (MBC) remains an incurable disease and a main cause of cancer death among women. An estimated 11,177 women in in Japan in 2006 [1] and 40,170 women in the United States in 2009 [2] died of breast cancer. Better means of assessing patient prognosis would aid in appropriate treatment planning and monitoring MBC. Serum tumor markers, such as carcinoembryonic antigen (CEA) and cancer antigen , are commonly used to monitor treatment effectiveness in clinical practice [3] [4] [5] [6] [7] [8] [9] . However, they are insufficient for predicting prognosis and do not provide therapeutic targets for improving prognosis. The detection of circulating tumor cells (CTCs) in peripheral blood is an independent predictor of the efficacy of systemic therapy and a prognostic marker in patients with MBC [10] [11] [12] [13] [14] [15] . In 2004, Cristofanilli et al. [11] reported that in patients diagnosed with measurable MBC, progression-free (PFS) and overall (OS) survival for patients with C5 CTCs per 7.5 ml peripheral blood (measured before initiation of a new line of therapy and at the first follow-up visit) were significantly shorter than for those in patients with\5 CTCs. Follow-up studies clarified the predictive value of CTCs for identifying chemotherapyresistant patients, enabling earlier adjustment of therapy [10, 12, 13] .
The expression of human epidermal growth factor receptor 2 (HER2) in CTCs was recently evaluated [16] [17] [18] [19] [20] . Interestingly, discordance in HER2 status between primary tumors and CTCs from the same patients was reported [17, 18, 20] : 5.0-38.0% of patients with HER2-negative primary breast cancers had HER2 overexpression in CTCs; however, the prognostic value of HER2 overexpression in CTCs for patients with HER2-negative primary breast cancer has not been determined. The purpose of this prospective study was to assess the prognostic value of HER2 status in CTCs in patients with MBC.
Materials and methods

Patients and sample collection
Fifty-six women with newly diagnosed MBC and started on systemic therapy or who changed to a new line of therapy because of disease progression were enrolled in this prospective study at St. Luke's International Hospital, Tokyo, Japan. The institutional review board approved the study protocol, and all patients gave informed consent. Inclusion criteria were as follows: invasive breast carcinoma diagnosed by histopathological findings, distant metastatic disease detected radiologically and/or pathologically, and HER2 status in the primary tumor confirmed. Patients with only local recurrences, skin metastases, and bilateral breast cancers were excluded. HER2 overexpression in the primary tumor was defined as a HercepTest score of 3? or 2? by immunohistochemical analysis using Ventana PATHWAY anti-HER2/neu (4B5) rabbit monoclonal antibody and recognized HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis. Primary tumor HER2 expression was determined by hospital pathologists. Blood specimens were collected at the initiation of the new line of therapy and at 3-to 4-week intervals up to 12 weeks. Patients remained in this study until their disease progressed and therapy was changed or until they died. Clinicians and patients were blinded to results of CTC counts. Before therapy initiation and after 12 weeks, computed tomography (CT) scans were performed to assess patients' radiological response to therapy. Response was determined by oncologists and radiologists according to the Response Evaluation Criteria in Solid Tumors (RECIST) [21] .
Isolation, enumeration, and HER2 evaluation of CTCs CTCs were counted using the CellSearch System (Veridex, LLC), an automated method cleared by the US Food and Drug Administration (FDA) and used for clinical monitoring in patients with MBC. First, patient blood samples were drawn into CellSave Preservative Tubes (Veridex). Samples were maintained at room temperature and processed within 72 h after collection. The CellTracks AutoPrep System, a semiautomated instrument for the preparation of samples, was used with the CellSearch Epithelial Cell Kit (Veridex) and Tumor Phenotyping Reagent HER2/neu (Veridex). CTCs were enriched immunomagnetically from 7.5 ml of blood using ferrofluids coated with antibodies targeting the epithelial cell adhesion molecule. Isolated cells were fluorescently labeled with the nucleic acid dye 4,2-diamidino-2-phenylindole dihydrochloride (DAPI), monoclonal antibodies specific for leukocytes (CD45 labeled with allophycocyanin), and epithelial cells (cytokeratins [10] 8, 18, and 19 labeled with phycoerythrin) to distinguish epithelial cells from leukocytes [11] . Epithelial cells were also examined for staining with a monoclonal antibody (HER81) specific for HER2 (HER2 labeled with fluorescein isothiocyanate). Identification and enumeration of CTCs were performed using the CellTracks Analyzer II, a semiautomated fluorescencebased microscopy system. Automatically selected images were reviewed independently by two operators for CTC identification. A third operator checked the selected images when the first two operators' results had discrepancies. CTCs were defined as nucleated cells that lacked CD45 and expressed creatine kinase (CK). Nucleated cells that expressed both CK and HER2 and lacked CD45 were defined as HER2-positive CTCs. For technical assessment, immunostaining was performed using HER2 antibody on SKBR-3 and MCF-7 cell lines. The strong staining detected in SKBR-3 cells (known to express high levels of HER2) was obviously different from the weak staining in MCF-7 cells (known to express low levels of HER2). Thus, strong staining of CTCs was defined as HER2 positivity.
After removal from the cartridge, cells were fixed on the slide glass. FISH was performed with centromeric alphasatellite DNA probes for chromosome 17 (CEP17) and with probes for the HER2 gene at chromosome 17q [22] . The copy numbers of HER2 gene and CEP17 sequences for each cell were determined with a magnification 1,0009 using an Olympus fluorescence microscope with a tripleband-pass filter. Data were analyzed in terms of both gene amplification and copy number change (increase or decrease in copy numbers). HER2 gene amplification was defined as C2.0 for the ratio of HER2 copy number to CEP17 copy number [18] . A maximum of 50 cells per sample were examined for HER2 amplification by FISH. Patients were diagnosed as having HER2-positive CTCs when they had at least one CTC in which HER2 was overexpressed and/or amplified.
Statistical analysis
Progression-free survival (PFS) was measured from the start date of systemic therapy or change to a new line of therapy to the date of first progression or last follow-up. Overall survival was measured to the date of death or to the date of last follow-up. PFS and OS were estimated with the Kaplan-Meier method and compared between groups using the log-rank statistic. Cox proportional hazards models were fit to determine the association of clinicopathologic factors with the risk of progression and death after adjustment for other patient and disease characteristics. Each model contained terms for age at diagnosis, presence of lymph node metastases at diagnosis, and HER2 and hormone receptor status in primary tumor. We calculated the sample size of HER2-positive CTCs to detect 35% difference in OS at 5% type-1 error and 80% power. Because there was no previous clinical study for HER2-positive CTCs, we referred the difference of 1 year survival rate between C5 CTCs and \5 CTCs at first follow-up in a previous study [12] and the expression rate of HER2 in primary tumors. A two-tailed P value\0.05 was considered statistically significant. All statistical analyses were done using SPSS version 17 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Of the original 56 patients enrolled, four were not included in analysis: one patient refused to undergo testing, one underwent surgery to control local bleeding, and two identified a history of contralateral breast cancer after enrolling in the study. Characteristics of the remaining 52 patients with MBC who started a new line of therapy are summarized in Table 1 . Forty-one patients (78.8%) had undergone surgery, whereas 11 patients had not because of the presence of metastatic disease at the time of diagnosis (de novo stage IV).
Median follow-up to determine OS was 655.0 (range 18-1,275) days. Two patients died before the first followup (3-4 weeks after the initiation of therapy), one died HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization before the second follow-up (8-9 weeks after the initiation of therapy), and one died before the last follow-up (12 weeks after the initiation of therapy); all four died of multiple liver metastases. Twelve patients died after the last follow-up. One patient's blood sample was not examined at the first follow-up. Radiographic tumor assessment showed that at 12 weeks, 21 patients had partial response, ten had stable disease, and 21 had progressive disease. The number of therapies patients received before this study was associated with PFS (P = 0.017) and OS (P = 0.006) in Cox regression analysis. Patient age, HER2 status, hormone receptor status, primary tumor size, and lymph node status were not statistically associated with PFS and OS (Tables 2, 3 ).
Circulating tumor cell counts
In 40 of 52 patients (76.9%), at least one CTC was detected during the study period. CTCs were detected in 31 of 52 patients (59.6%) at baseline and in 21 of 49 patients (42.9%) at first follow-up; two patients who died and one whose blood was not examined were excluded from the latter analysis. Mean CTC count of the 52 patients at baseline was six (median 304; range 0-6,067). At baseline, C5 CTCs was associated with a significantly shorter PFS (n = 18; median 91.0 days; P = 0.044) and OS (median 356.0 days; P = 0.029) duration compared with that for patients with a count of \5 CTCs (n = 34; median 437.0 days, and median 915.0 days, respectively) in log-rank analysis. At first follow-up, a count of C5 CTCs was associated with a significantly shorter PFS (n = 9; median 85.0 days; P = 0.015) and OS (median 146.0 days; P = 0.007) duration compared with that for patients with a count of\5 CTCs (n = 40; median 356.0 days, and median 878.0 days, respectively) (Fig. 1a, b ).
HER2 expression in CTCs
We further assessed the prognostic value of HER2 status in CTCs. Changes in CTC counts and HER2 status in CTCs are shown in Table 4 . At baseline, HER2-positive CTCs were present in eight patients (15.4%) and HER2-negative CTCs in 23 patients (44.2%). HER2-positive CTCs were diagnosed in eight patients by FISH and five by immunocytochemistry (ICC). Fourteen of 52 patients (26.9%) had HER2-positive CTCs during the study period. We observed a change of HER2 status in CTCs at the first follow-up. Among the eight patients with HER2-positive CTCs at baseline, at the first follow-up, three still had HER2-positive CTCs, four no longer had HER2-positive CTCs, and one was not assessed because she had died. In contrast, among 23 patients with HER2-negative CTCs at baseline, three had HER2-positive CTCs at the first follow-up, whereas 20 still did not have HER2-positive CTCs. One patient without CTCs at baseline had acquired HER2-negative CTCs at first follow-up. Of the six patients with HER2-positive CTCs at first follow-up, five were by FISH and three by ICC. Fig. 1 Kaplan-Meier functions of a progression-free survival (PFS) in patients with C5 circulating tumor cells (CTCs) (n = 9) and patients with \5 CTCs (n = 40) at first follow-up (log-rank P = 0.015), b overall survival (OS) in patients with C5 CTCs (n = 9) and patients with \5 CTCs (n = 40) at first follow-up (logrank P = 0.007), c PFS in patients with human epidermal growth factor receptor 2 (HER2)-positive CTCs (n = 6) and patients without HER2-positive CTCs (n = 43) at first follow-up (log-rank P = 0.001), and d )S in patients with HER2-positive CTCs (n = 6) and patients without HER2-positive CTCs (n = 43) at first follow-up (log-rank P = 0.013)
At baseline, HER2-positive CTCs were not associated with PFS (P = 0.804) or OS duration (P = 0.676). However, at first follow-up, patients with HER2-positive CTCs had a significantly shorter PFS (n = 6; median 146.0 days; P = 0.001) and OS (median 146.0 days; P = 0.013) duration than did patients without HER2-positive CTCs (n = 43; median 878.0 and 356.0 days, respectively) (Fig. 1c, d) . In multivariate analysis, HER2-positive CTCs at first follow-up (P = 0.029) and the number of therapies patients received before this study (P = 0.006) were independent factors in terms of PFS ( Table 2 ). The number of therapies (P = 0.001) and C5 CTCs (P = 0.043) at baseline were independent factors in terms of OS (Table 3) . We assessed concordance of HER2 status between primary tumors and CTCs among patients with CTCs. At baseline, three of 22 patients (13.6%) with HER2-negative primary tumors had HER2-positive CTCs. In contrast, four of nine patients (44.4%) with HER2-positive primary tumors had HER2-negative CTCs (Table 5) 
Discussion
We prospectively demonstrated that HER2-positive CTCs predicted a worse prognosis in MBC and thus that HER2 status in CTCs may serve as a prognostic factor. Our results also showed that HER2-positive CTCs can be present in patients with HER2-negative primary tumors. Our results confirmed Cristofanilli et al.'s landmark finding of CTC count as a prognostic factor [11] [12] [13] [14] [15] . Table 5 summarizes previous studies that evaluated HER2 expression status in CTCs [17] [18] [19] [20] [23] [24] [25] [26] [27] . Many previous studies evaluated HER2 by reverse transcriptase-polymerase chain reaction (RT-PCR) or FISH, and in these studies, HER2-positive CTCs were detected in 21.6-64.9% of patients with CTCs. HER2-positive CTCs were detected in 19.2-50% of patients with HER2-negative primary breast tumors [19, [23] [24] [25] [26] and 0-29% of patients with MBC who had HER2-negative primary tumors [17, 18, 20, 27] . We evaluated HER2 status in CTCs by both ICC and FISH because the method of determining HER2 expression status in CTCs has not been standardized. Our findings concur with these previous results.
Our study is the first to examine the prognostic role of HER2-positive CTCs in patients with MBC. Three studies in which the presence and frequency of HER2-positive CTCs correlated with significantly decreased disease-free and OS durations [19, 23, 25] were conducted in patients with primary breast cancer. Previous studies of prognosis compared patients with HER2-positive CTCs to patients with HER2-negative CTCs or without CTCs at baseline only. The other unique aspect of our study is that we evaluated prognosis by comparing patients with HER2-positive and HER2-negative CTCs at baseline and also at first follow-up; thus, the change in CTC HER2 status was considered. At first follow-up a count of C5 CTCs and HER2-positive CTCs were significantly associated with PFS and OS in univariate analysis. Because HER2 positivity in CTCs depended on CTC counts, the prognostic role of HER2-positive CTCs would be statistically interfered by a count of C5 CTCs in multivariate analysis. Therefore, we included HER2-positive CTCs only to determine the independent factors. We demonstrated that HER2-positive CTCs not at baseline but at first follow-up were associated with PFS. This result indicates that HER2-positive CTCs at first follow-up predict resistance to treatment. Therefore, the presence of HER2-positive CTCs at first follow-up may suggest early change of treatment. In terms of OS, a C5 CTCs at baseline was an independent factor rather than HER2-positive CTCs. The presence of HER2-positive CTCs may be a prognostic factor regardless of primary tumor HER2 status. Notably, five of eight patients with HER2-negative primary tumors and HER2-positive CTCs died during the follow-up period. Furthermore, four of those patients died within 144 days of initiation of therapy. In contrast, three of four patients with HER2-positive CTCs who received trastuzumab because of their HER2-positive primary tumors lost HER2 overexpression in CTCs; the fourth patient died of multiple liver metastases 31 days after the initiation of therapy. Meng et al. [18] retrospectively reported that two of four patients with HER2-positive CTCs and HER2-negative primary tumors who were treated with trastuzumab-containing chemotherapy responded. These significant data clearly suggest the need to develop prospective studies to determine the potential role of trastuzumab or other HER2-targeted therapies for patients with HER2-positive CTCs and HER2-negative primary tumors.
One other note is that we used different antibodies to detect HER2 expression in CTCs and primary tumors. These antibodies were selected to make sure that we could compare our results with those of previous studies because the antibody for CTCs was used in previous studies [17, 18, 24, 26] . There is a small possibility that the use of different antibodies might have caused discrepant positivity between CTCs and primary tumors.
In summary, we believe that the finding of the prognostic value of HER2-positive CTCs at first follow-up of patients with HER2-negative MBC is of critical relevance in a population with poor prognosis that is treated with palliative intent. We plan to perform additional, well-powered, clinical studies to evaluate the discordance of HER2 status among patients' primary tumors and CTCs and to assess the potential of additional HER2-targeting therapy.
